BrainEver
Elizabeth Di Lullo has a diverse work experience spanning nearly two decades. Elizabeth currently holds the position of Associate Director Discovery Biology at BrainEver since January 2023. Prior to that, they were a Senior Scientist at the same company starting from September 2021. Before joining BrainEver, they worked as a Senior Scientist at GOURMEY from September 2020 to March 2021.
Elizabeth's research experience includes being a Specialist - Post Doctoral Research Fellow at UCSF from May 2013 to April 2019. Elizabeth also worked as a Postdoctoral Research Scientist at Collège de France from September 2011 to December 2012. Additionally, they were a PHD Candidate at Collège de France from September 2007 to September 2011.
Elizabeth Di Lullo began their career as an Editorial Assistant at Leukemia Journal from June 2004 to June 2005. Overall, they have demonstrated a strong commitment to research and has held various positions in biology and scientific research.
Elizabeth Di Lullo's education history includes a Bachelor of Science (BS) degree in Neuroscience from UCL, which they obtained from 1999 to 2003. Elizabeth then pursued a Master of Science (MS) degree in Physiology and Neuroscience at Pierre and Marie Curie University, completing it from 2005 to 2007. Later, they attended Ecole normale supérieure/College de France, where they obtained their Doctor of Philosophy (PhD) in Neuroscience from 2007 to 2011.
This person is not in any teams
BrainEver
BrainEver’s innovative therapeutic strategy is a translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life and control several neuronal functions, including metabolism and epigeneticstability.BrainEver makes the hypothesis that, in patients, homeoprotein administration could durably modify the physiological resistance of surviving neurons while increasing their activity, thus leading to the improvement of clinical symptoms.Different homeoproteins that could be important in different neurodegenerative pathologies are being explored, the most advanced being Engrailed 1 (BREN01) for the treatment of Parkinson Disease and Amyotrophic Lateral Sclerosis (ALS).Beside Engrailed 1 in Parkinson Disease and ALS, BrainEver is currently generating a pipeline of 4 drug candidates targeting other neurodegenerative disease like Huntington Disease and Optic Neuropathies.